FDA Approvals | Gene therapy
Products regulated by the Food and Drug Administration comprise 25% of American consumer spending. The approaches used to approve these products can be as varied and complex as the products themselves. Such differences are dictated by Federal law and FDA identifies and enforces the relative risks and benefits that the products pose to consumers. These results convey summaries of products approved by FDA, including information about their past history and present status. The information not only applies to New Molecular Entities, but includes FDA approval information pertaining to new ingredients, dosages, therapeutic uses and generic equivalents.
Top 5 innovator ingredients
Top 5 generic ingredients
- None
Top 5 innovator sponsors
- Sarepta Therapeutics (3)
- bluebird bio (2)
- Novartis (2)
- PTC Therapeutics (1)
- Spark Therapeutics (1)
Top 5 generic sponsors
- None
Note: these approvals are sourced from Drugs@FDA and Purple Book, and do not currently reflect older FDA approvals and/or other evidence of US marketing.
Active Ingredients
| Active Ingredient | Innovator Sponsor | Approval Years | Innovator Years | Innovator | Generic | Type |
|---|---|---|---|---|---|---|
| voretigene neparvovec | Spark Therapeutics | 2017 | 2017 | 1 | 0 | Gene therapy |
| golodirsen | Sarepta Therapeutics | 2019 | 2019 | 1 | 0 | Gene therapy |
| onasemnogene abeparvovec | Novartis | 2019 - 2025 | 2019 - 2025 | 2 | 0 | Gene therapy |
| casimersen | Sarepta Therapeutics | 2021 | 2021 | 1 | 0 | Gene therapy |
| etranacogene dezaparvovec | CSL Behring | 2022 | 2022 | 1 | 0 | Gene therapy |
| lentiglobin bb305 | bluebird bio | 2022 | 2022 | 1 | 0 | Gene therapy |
| nadofaragene firadenovec | Ferring | 2022 | 2022 | 1 | 0 | Gene therapy |
| beremagene geperpavec | Krystal Biotech, Inc. | 2023 | 2023 | 1 | 0 | Gene therapy |
| delandistrogene moxeparvovec | Sarepta Therapeutics | 2023 | 2023 | 1 | 0 | Gene therapy |
| lovotibeglogene autotemcel | bluebird bio | 2023 | 2023 | 1 | 0 | Gene therapy |
| valoctocogene roxaparvovec | Biomarin | 2023 | 2023 | 1 | 0 | Gene therapy |
| Eladocagene Exuparvovec | PTC Therapeutics | 2024 | 2024 | 1 | 0 | Gene therapy |
| fidanacogene elaparvovec | Pfizer | 2024 | 2024 | 1 | 0 | Gene therapy |
13 ingredients
Page 1 / 1
Sponsor Organizations
| Sponsor | Approval Years | Innovator Years | Innovator | Generic | Org Type |
|---|
Approval Applications
| Appl No | Type | Approval | Sponsor | Active Ingredients | Marketing Status | Class | Priority? | Links |
|---|
Submission class glossary
- TYPE 1
- New Molecular Entity
- TYPE 2
- New Active Ingredient
- TYPE 3
- New Dosage Form
- TYPE 4
- New Combination
- TYPE 5
- New Formulation or New Manufacturer
- TYPE 6
- New Indication (pre-2009)
- TYPE 7
- Drug Already Marketed without Approved NDA
- TYPE 8
- Partial Rx to OTC Switch
- TYPE 9
- New Indication or Claim (existing NDA)
- TYPE 10
- New Indication or Claim (additional NDA)
- MEDGAS
- Medical Gas